Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed question first answered answering member label attachment file name title
tabling member	label

Search

1064177

	registered interest
	date	19/02/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	General Practitioners: Pensions
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what estimate they have made of the numbers of GPs who have left the NHS pension scheme aged between (1) 50 and 55, and (2) 55 and 59, years old in (a) 2015, (b) 2016, (c) 2017, and (d) 2018.
	tabling member printed	Baroness Altmann
	uin	HL13824
	answer	answer is ministerial correction date of answer 05/03/2019 answer text <p>The information is not collected in the format requested and to obtain it would incur disproportionate cost. The NHS Pension Scheme is administered by the NHS Business Services Authority, who do not collect data on the number of retirements in the specific age groups requested.</p><p> </p><p>General practitioners (GPs) may leave the scheme for various reasons, such as claiming a pension on normal age grounds at or beyond normal pension age, claiming a pension early on ill-health grounds, claiming a pension on voluntary early retirement grounds, or opting out of the scheme. Information is not currently available on the number of GPs who have opted out of the scheme disaggregated from broader scheme membership.</p> answering member printed Baroness Blackwood of North Oxford question first answered 05/03/2019 14:38:21 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
	tabling member	4533 label Biography information for Baroness Altmann

933732

	registered interest
	date	02/07/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Radiotherapy
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what plans they have to ensure radiotherapy treatment for NHS patients is not interrupted if there is no withdrawal deal agreed with the European Union before March 2019
	tabling member printed	Baroness Altmann
	uin	HL9119
	answer	answer is ministerial correction date of answer 16/07/2018 answer text <p>The Government is confident of securing a withdrawal deal with the European Union before we leave in March 2019. However, we are preparing for all potential outcomes, including the unlikely scenario in which a mutually satisfactory agreement cannot be reached.</p><p>The Department is currently undertaking a risk assessment of the supply chain for all medicines and treatments, including radiotherapy, used on the National Health Service. This will ensure that any potential impact on the availability of medicines and medical isotopes for the NHS arising from the United Kingdom’s withdrawal from the EU are identified and managed.</p> answering member printed Lord O'Shaughnessy question first answered 16/07/2018 12:10:22 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann

924159

	registered interest
	date	14/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government, following the recent meeting of the Joint Committee on Vaccinations and Immunisation (JCVI), whether they have received a recommendation from the JCVI regarding the extension of the human papillomavirus vaccination to all boys; and if so, when they will announce their decision in this regard.
	tabling member printed	Baroness Altmann
	uin	HL8638
	answer	answer is ministerial correction date of answer 27/06/2018 answer text <p>The Department has not yet received the Joint Committee on Vaccination and Immunisation’s final advice on human papillomavirus vaccination for boys. The Department expects to receive this advice imminently and will consider this as a matter of priority. A decision will be made as soon as possible.</p> answering member printed Lord O'Shaughnessy question first answered 27/06/2018 14:13:47 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann

924160

	registered interest
	date	14/06/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government what is the Joint Committee on Vaccination and Immunisation's latest assessment of the proportion of cancers which are caused by vaccine-preventable types of human papillomavirus.
	tabling member printed	Baroness Altmann
	uin	HL8639
	answer	answer is ministerial correction date of answer 27/06/2018 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published an interim statement on extending the human papillomavirus (HPV) vaccination to adolescent boys in July 2017. The interim statement and the following table set out the proportion of cancers attributable to HPV infection by disease, as modelled by Public Health England (PHE). A copy of the JCVI Interim Statement on Extending HPV Vaccination to Adolescent Boys is attached.</p><p> </p><table><tbody><tr><td><p>Cancer site (females)</p></td><td><p>High-risk HPV type (attribution fraction)</p></td></tr><tr><td><p>Cervix</p></td><td><p>HPV16/18/31/33/45/52/58/other (35/39/51/56/59/68) (95.1%)</p></td></tr><tr><td><p>Vulva</p></td><td><p>HPV16/18/33 (12.7%)</p></td></tr><tr><td><p>Vagina</p></td><td><p>HPV16 (53.7%)</p></td></tr><tr><td><p>Anus</p></td><td><p>HPV16/18/33 (77.0%)</p></td></tr><tr><td><p>Oropharynx</p></td><td><p>HPV16 (24.7%)</p></td></tr><tr><td><p>Oral cavity</p></td><td><p>HPV16/18 (1.1%)</p></td></tr><tr><td><p>Larynx</p></td><td><p>HPV16/18 (1.9%)</p></td></tr></tbody></table><p> </p><table><tbody><tr><td><p>Cancer site (males)</p></td><td><p>High-risk HPV type (attribution fraction)</p></td></tr><tr><td><p>Anus</p></td><td><p>HPV16/18/33 (77.0%)</p></td></tr><tr><td><p>Penis</p></td><td><p>HPV16/18 (28.6%)</p></td></tr><tr><td><p>Oropharynx</p></td><td><p>HPV16 (12.8%)</p></td></tr><tr><td><p>Oral cavity</p></td><td><p>HPV16/18 (1.4%)</p></td></tr><tr><td><p>Larynx</p></td><td><p>HPV16/18 (0.6%)</p></td></tr></tbody></table><p> </p><p>Note:</p><p> </p><p>Attributable fraction for high risk HPV types associated with cancer as modelled by PHE and based on International Agency for Research on Cancer reviews.</p><p> </p><p>The JCVI most recently considered HPV vaccination on 6 June 2018, and the minutes of that meeting will be published on or before 18 July 2018.</p> answering member printed Lord O'Shaughnessy question first answered 27/06/2018 14:06:23 answering member 4545 label Biography information for Lord O'Shaughnessy attachment 1 file name Extending_HPV_Vaccination.pdf title Extending_HPV_Vaccination
	tabling member	4533 label Biography information for Baroness Altmann

874354

	registered interest
	date	28/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government when they expect to receive the final report from the Joint Committee on Vaccinations and Immunisation relating to the extension of HPV vaccination to adolescent boys.
	tabling member printed	Baroness Altmann
	uin	HL6740
	answer	answer is ministerial correction date of answer 09/04/2018 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) is currently reviewing evidence on the impact and cost-effectiveness of extending the human papillomavirus vaccination programme to adolescent boys. This includes mathematical modelling being undertaken by Public Health England.</p><p>In February 2018 JCVI agreed that it needed to see the results of the independent peer review of the modelling work, and the additional analyses being undertaken, before concluding its advice. The JCVI further agreed that legal advice should be obtained in response to stakeholder correspondence.</p><p>Once JCVI has reached a decision, the Committee’s advice will be published most likely in the form of a statement alongside the minutes of the relevant meeting. The JCVI will not be in a position to conclude its advice until the required modelling, peer review and legal advice has been considered. This work will continue through 2018 and timeframes for JCVI concluding its advice are dependent on completion of the analyses requested.</p> answering member printed Lord O'Shaughnessy question first answered 09/04/2018 14:45:14 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann

874355

	registered interest
	date	28/03/2018
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Human Papillomavirus: Vaccination
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty's Government whether they have taken legal advice relating to whether the failure to vaccinate all young boys against HPV virus constitutes discrimination under the Equality Act 2010 or other equality legislation.
	tabling member printed	Baroness Altmann
	uin	HL6741
	answer	answer is ministerial correction date of answer 09/04/2018 answer text <p>The Joint Committee on Vaccination and Immunisation is currently considering whether the human papillomavirus vaccination programme for girls, which was introduced in 2008 primarily to protect against cervical cancer, should be extended to include adolescent boys. The Department will consider its final advice once it has been received.</p><p>Any on-going legal discussions related to this issue are subject to legal professional privilege. The Government will ensure that any decision taken is fully compliant with relevant equality legislation.</p> answering member printed Lord O'Shaughnessy question first answered 09/04/2018 14:44:42 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann

677369

	registered interest
	date	23/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Social Services: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government whether they have considered introducing specific savings incentives to help people prepare for social care costs in later life; if so, why they have not been introduced; and if not, why not.
	tabling member printed	Baroness Altmann
	uin	HL4835
	answer	answer is ministerial correction date of answer 03/02/2017 answer text <p>The Government recognises that there needs to be reform in the medium and long term to reduce variation and ensure high quality care across the whole country. It is interested in considering the full range of options to do this, including savings incentives as a possible longer-term solution.</p> answering member printed Lord O'Shaughnessy question first answered 03/02/2017 14:21:56 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann

677370

	registered interest
	date	23/01/2017
	answering body	Department of Health
	answering dept id	17
	answering dept short name	Health
	answering dept sort name	Health
	hansard heading	Social Services: Fees and Charges
	house id	2
	legislature	25277 pref label House of Lords
	question text	To ask Her Majesty’s Government what discussions they have had with the savings industry about (1) new insurance products to help provide for later life care needs, and (2) new savings products to help people provide for later life care needs; when any such discussions took place; and whether they were productive.
	tabling member printed	Baroness Altmann
	uin	HL4836
	answer	answer is ministerial correction date of answer 01/02/2017 answer text <p>Officials have met regularly with representatives of the insurance industry for productive discussions on a range of issues, including the availability of insurance and savings products to cover the costs of care.</p> answering member printed Lord O'Shaughnessy question first answered 01/02/2017 17:52:41 answering member 4545 label Biography information for Lord O'Shaughnessy
	tabling member	4533 label Biography information for Baroness Altmann